Table V.
Association of miR-24 expression and clinical features with the risk of relapse to ALL.
| Without relapse n (%) |
With relapse n (%) |
P-value | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||
| OR | CI 95% | P-valuea | OR | CI 95% | P-valueb | ||||
| Gender | |||||||||
| Female | 16 (41.03) | 25 (34.72) | 0.542 | 1.00 | |||||
| Male | 23 (58.97) | 47 (65.28) | 1.31 | 0.59–2.91 | 0.512 | ||||
| Immunophenotype | |||||||||
| B-lineage | 36 (92.31) | 57 (79.17) | 1.00 | ||||||
| T-lineage | 2 (5.13) | 9 (12.50) | 0.198 | 2.84 | 0.58–13.90 | 0.197 | |||
| B/T-lineage | 1 (2.56) | 6 (8.33) | 3.78 | 0.44–32.78 | 0.226 | ||||
| B-lineage | 36 (92.31) | 57 (79.17) | 1.00 | ||||||
| T-lineage + B/T-lineage | 3 (7.69) | 15 (20.83) | 0.105 | 3.15 | 0.85–11.67 | 0.085 | |||
| FAB classification | |||||||||
| ALL | |||||||||
| L1 | 31 (79.49) | 62 (86.11) | 1.60 | 0.57–4.46 | 0.369 | ||||
| L2 | 8 (20.51) | 10 (13.89) | 0.423 | 1.00 | |||||
| Risk by age and leukocytes at diagnosis | |||||||||
| Low-risk (1–10 years and <50,000 leukocytes/mm3) | 27 (69.23) | 21 (29.17) | <0.001c | 1.00 | |||||
| High-risk (<1 and >10 years and >50,000 leukocytes/mm3) | 12 (30.77) | 51 (70.83) | 5.46 | 2.34–12.77 | <0.001c | 5.20 | 2.19–12.32 | <0.001c | |
| miR-24 levels | |||||||||
| Downregulated | 27 (69.23) | 34 (47.22) | 0.030c | 1.00 | |||||
| Upregulated | 12 (30.77) | 38 (52.78) | 2.51 | 1.10–5.72 | 0.028c | 2.27 | 1. 94–5.51 | 0.020c | |
OR, odds ratio; CI, confidence interval;
a
p-value was obtained by logistic regression analysis, taking reference to female, B-lineage, L2, 1–10 years, <50,000 leukocytes/mm3 (low-risk) and downregulated levels of miR-24.
b
p-value was obtained by multivariate logistic regression analysis.
c
Significant p<0.05, ALL, acute lymphoblastic leukemia.